← Leaderboards
John D Belcher
Hillhurst Biopharmaceuticals, Inc.
$2,490,337
Attributed
$5,519,508
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2016–24$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,519,508 · 5
By mechanism
UG3$2,111,258 · 1
R44$1,972,708 · 1
UH3$728,111 · 1
OT2$407,623 · 1
R43$299,808 · 1
Top collaborators
- Edward Gomperts6 shared
- Donald A Simone2 shared
Most similar at Hillhurst Biopharmaceuticals, Inc.
Same institution · by research overlap
- Edward Gomperts$8,146,154
- Donald A Simone$12,911,965
- Ravirajsinh Jadeja$1,122,113
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainInflammationSickle Cell AnemiaDoseSickle CellToxicologyPreventOralClinical ResearchPropertyDrug KineticsHealthy VolunteerInflammatoryFormulationInnovationSafetyMedicalMouse ModelClinical TrialsOral AdministrationBaseBlood VesselsErythrocytesGlutamine
Grant awards (8)
Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease$728,111
UH3 · FY2024 · NS
Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease$2,111,258
UG3 · FY2022 · NS
Circulating Endothelial Cells and Microvesicles as Biomarkers for Gene Therapy in Sickle Cell Disease$300,000
OT2 · FY2020 · HL · contact PI
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$702,410
R44 · FY2019 · HL
Circulating Endothelial Cells and Microvesicles as Biomarkers for Gene Therapy in Sickle Cell Disease$107,623
OT2 · FY2019 · HL · contact PI
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$1,270,298
R44 · FY2018 · HL
Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$41,551
R43 · FY2017 · HL
Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease$258,257
R43 · FY2016 · HL